A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Two Doses of DR-3001 Versus Placebo in Women With Overactive Bladder
Latest Information Update: 24 Jul 2016
At a glance
- Drugs Oxybutynin (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00685113).
- 19 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00685113).
- 16 Dec 2009 Planned end date changed from Mar 2010 to Jul 2010 as reported by ClinicalTrials.gov.